ES2572231T3 - Anticuerpos monoclonales anti-IL-21 humana - Google Patents
Anticuerpos monoclonales anti-IL-21 humanaInfo
- Publication number
- ES2572231T3 ES2572231T3 ES11185989T ES11185989T ES2572231T3 ES 2572231 T3 ES2572231 T3 ES 2572231T3 ES 11185989 T ES11185989 T ES 11185989T ES 11185989 T ES11185989 T ES 11185989T ES 2572231 T3 ES2572231 T3 ES 2572231T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- variable region
- chain variable
- human anti
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
Abstract
Anticuerpo monoclonal anti-IL-21 humana o fragmento de unión a antígeno del mismo, cuyo dicho anticuerpo monoclonal o fragmento de unión a antígeno comprende: (a) una región de cadena pesada que comprende: (i) una CDR1 de la región variable de cadena pesada que comprende la SEQ ID NO: 63; (ii) una CDR2 de la región variable de cadena pesada que comprende la SEQ ID NO: 65; y (iii) una CDR3 de la región variable de cadena pesada que comprende la SEQ ID NO: 67; y (b) una región de cadena ligera que comprende: (i) una CDR1 de la región variable de cadena ligera que comprende la SEQ ID NO: 71; (ii) una CDR2 de la región variable de cadena ligera que comprende la SEQ ID NO: 73; y (iii) una 10 CDR3 de la región variable de cadena ligera que comprende la SEQ ID NO: 75.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1232907P | 2007-12-07 | 2007-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2572231T3 true ES2572231T3 (es) | 2016-05-30 |
Family
ID=40899470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08878088.7T Active ES2584237T3 (es) | 2007-12-07 | 2008-12-08 | Anticuerpos monoclonales anti-IL-21 humana |
| ES11185989T Active ES2572231T3 (es) | 2007-12-07 | 2008-12-08 | Anticuerpos monoclonales anti-IL-21 humana |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08878088.7T Active ES2584237T3 (es) | 2007-12-07 | 2008-12-08 | Anticuerpos monoclonales anti-IL-21 humana |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US7883700B2 (es) |
| EP (3) | EP2217268B1 (es) |
| JP (3) | JP5745274B2 (es) |
| KR (2) | KR101591316B1 (es) |
| CN (2) | CN102027011B (es) |
| AU (1) | AU2008364115B2 (es) |
| BR (1) | BRPI0821168B8 (es) |
| CA (2) | CA2910933C (es) |
| DK (1) | DK2217268T3 (es) |
| ES (2) | ES2584237T3 (es) |
| HU (1) | HUE027828T2 (es) |
| IL (2) | IL205976A (es) |
| MX (1) | MX2010006181A (es) |
| PL (1) | PL2217268T3 (es) |
| PT (1) | PT2217268T (es) |
| RU (1) | RU2504552C2 (es) |
| WO (1) | WO2010055366A2 (es) |
| ZA (1) | ZA201004046B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070122413A1 (en) | 2005-11-28 | 2007-05-31 | Sivakumar Pallavur V | Il-21 antagonists |
| EP2217268B1 (en) | 2007-12-07 | 2016-05-04 | ZymoGenetics, Inc. | Anti-human il-21 monoclonal antibodies |
| US20130224109A1 (en) * | 2010-07-20 | 2013-08-29 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods featuring il-6 and il-21 antagonists |
| US20130323259A1 (en) * | 2011-01-17 | 2013-12-05 | Novo Nordisk A/S | Il-21 ligands |
| WO2012164021A1 (en) | 2011-05-31 | 2012-12-06 | Novo Nordisk A/S | Il-21 epitope and il-21 ligands |
| EP2768859B1 (en) * | 2011-10-19 | 2018-02-21 | MorphoSys AG | Antagonists of il17c for the treatment of inflammatory disorders |
| EP2746293A1 (en) | 2012-12-21 | 2014-06-25 | Novo Nordisk A/S | Anti-IL21 antibodies for use in the treatment of cardiovascular diseases |
| US20140178395A1 (en) * | 2012-12-21 | 2014-06-26 | Novo Nordisk A/S | Treatment of nephropathy |
| WO2014205501A1 (en) * | 2013-06-27 | 2014-12-31 | Monash University | Il-21 binding proteins and uses thereof |
| CN103487572B (zh) * | 2013-10-08 | 2017-03-29 | 北京大学人民医院 | 滤泡辅助性T淋巴细胞(Tfh)在自身免疫性疾病病情预警中的应用 |
| CN104721820A (zh) * | 2013-12-24 | 2015-06-24 | 信达生物制药(苏州)有限公司 | 双特异性单克隆抗体在治疗葡萄膜炎中的用途 |
| WO2015132241A1 (en) * | 2014-03-03 | 2015-09-11 | Novo Nordisk A/S | Treatment of inflammatory diseases |
| AR099625A1 (es) | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| AU2015244025B2 (en) | 2014-04-08 | 2019-03-21 | Boston Pharmaceuticals Inc. | Binding molecules specific for IL-21 and uses thereof |
| PT3139948T (pt) * | 2014-05-07 | 2020-05-22 | Novo Nordisk As | Tratamento de diabetes usando glp-1 e anti-il-21 |
| JP6672175B2 (ja) * | 2014-05-07 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療 |
| RU2609627C2 (ru) * | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| CN107249633A (zh) * | 2014-12-19 | 2017-10-13 | 迈博太科公司 | 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法 |
| EP3233120A4 (en) | 2014-12-19 | 2018-05-30 | Monash University | Il-21 antibodies |
| CA3018792C (en) | 2016-03-31 | 2023-03-28 | Eli Lilly And Company | Il-21 antibodies and uses thereof |
| US20190185559A1 (en) * | 2016-09-02 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| JP6952295B2 (ja) * | 2016-09-09 | 2021-10-20 | 国立大学法人金沢大学 | ヒト抗ｈｌａモノクローナル抗体の作製方法 |
| CN118126157A (zh) | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
| MX2020007291A (es) | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| KR20230038496A (ko) * | 2020-07-13 | 2023-03-20 | 트랜스진 | 면역 억제의 치료 |
| CN118370816A (zh) * | 2024-03-22 | 2024-07-23 | 中日友好医院(中日友好临床医学研究所) | Il-2/抗il-2抗体免疫复合物的应用 |
| WO2025257327A1 (en) | 2024-06-13 | 2025-12-18 | Almirall, S.A. | Therapeutic approaches for the management of hidradenitis suppurativa |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| UA84387C2 (ru) | 1999-03-09 | 2008-10-27 | Займодженетикс, Инк. | Человеческий цитокин как лиганд зальфа рецептора и его применение |
| ES2279809T3 (es) | 2000-04-05 | 2007-09-01 | Zymogenetics, Inc. | Receptores de citoquina zalfa11 solubles. |
| ES2286128T3 (es) | 2000-06-30 | 2007-12-01 | Zymogenetics, Inc. | Proteina zcyto21 tipo interferon. |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| PL403488A1 (pl) | 2001-05-24 | 2013-07-08 | Zymogenetics, Inc. | Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina |
| EP2130919A1 (en) * | 2001-11-05 | 2009-12-09 | ZymoGenetics, Inc. | IL-21 antagonists |
| US20040028665A1 (en) * | 2002-01-08 | 2004-02-12 | Garner Bryan E. | Compositions and methods for inhibiting pathogenic growth |
| AU2003230834A1 (en) | 2002-04-09 | 2003-10-27 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| MXPA04012116A (es) | 2002-06-07 | 2005-04-19 | Zymogenetics Inc | Uso del il-21 en cancer y otras aplicaciones terapeuticas. |
| MXPA05000655A (es) * | 2002-07-15 | 2006-02-22 | Harvard College | Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th). |
| KR20050065587A (ko) | 2002-10-08 | 2005-06-29 | 이뮤노메딕스, 인코오포레이티드 | 항체 치료법 |
| US20070092485A1 (en) * | 2002-11-15 | 2007-04-26 | Zymogenetics, Inc. | Cytokine zalpha11 ligand |
| MXPA05006117A (es) | 2002-12-13 | 2005-09-30 | Zymogenetics Inc | Produccion de il-21 en hospederos procarioticos. |
| AU2003294930B2 (en) | 2002-12-23 | 2008-12-04 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same |
| MXPA05009556A (es) * | 2003-03-14 | 2005-11-16 | Wyeth Corp | Anticuerpos contra receptor de il-21 humano y sus usos. |
| RU2005132458A (ru) * | 2003-03-21 | 2006-03-20 | Уайт (Us) | Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21 |
| EP1680138B1 (en) | 2003-10-17 | 2013-07-17 | Novo Nordisk A/S | Combination therapy |
| JP4471721B2 (ja) | 2004-04-20 | 2010-06-02 | 独立行政法人産業技術総合研究所 | 抗インターロイキン２１受容体（ｉｌ−２１ｒ）抗体および本抗体を産生するハイブリドーマ |
| EP1753458A4 (en) * | 2004-05-19 | 2009-07-22 | Wyeth Corp | MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| MX2007001509A (es) | 2004-08-05 | 2007-03-27 | Wyeth Corp | Antagonismo de la actividad del receptor de interleuquina 21. |
| KR100654124B1 (ko) | 2004-11-18 | 2006-12-08 | 주식회사 하이닉스반도체 | 벙커 디펙트를 억제할 수 있는 반도체 소자 제조 방법 |
| ITRM20040586A1 (it) * | 2004-11-29 | 2005-02-28 | Giuliani Spa | Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico. |
| WO2006105538A2 (en) * | 2005-03-31 | 2006-10-05 | Centocor, Inc. | Methods and compositions for treating il-21 related pathologies |
| DK200501310A (da) * | 2005-09-21 | 2005-10-01 | Novo Nordisk As | The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults |
| US20070122413A1 (en) * | 2005-11-28 | 2007-05-31 | Sivakumar Pallavur V | Il-21 antagonists |
| EP1960433A2 (en) * | 2005-11-28 | 2008-08-27 | Zymogenetics, Inc. | Il-21 receptor antagonists |
| EP2217268B1 (en) | 2007-12-07 | 2016-05-04 | ZymoGenetics, Inc. | Anti-human il-21 monoclonal antibodies |
-
2008
- 2008-12-08 EP EP08878088.7A patent/EP2217268B1/en active Active
- 2008-12-08 MX MX2010006181A patent/MX2010006181A/es active IP Right Grant
- 2008-12-08 BR BRPI0821168A patent/BRPI0821168B8/pt active IP Right Grant
- 2008-12-08 ES ES08878088.7T patent/ES2584237T3/es active Active
- 2008-12-08 HU HUE08878088A patent/HUE027828T2/en unknown
- 2008-12-08 WO PCT/IB2008/005011 patent/WO2010055366A2/en not_active Ceased
- 2008-12-08 KR KR1020107014852A patent/KR101591316B1/ko active Active
- 2008-12-08 CA CA2910933A patent/CA2910933C/en active Active
- 2008-12-08 US US12/330,334 patent/US7883700B2/en active Active
- 2008-12-08 ES ES11185989T patent/ES2572231T3/es active Active
- 2008-12-08 PT PT88780887T patent/PT2217268T/pt unknown
- 2008-12-08 CN CN200880126330.8A patent/CN102027011B/zh active Active
- 2008-12-08 KR KR1020167002415A patent/KR101615215B1/ko active Active
- 2008-12-08 CN CN201310148259.6A patent/CN103772502B/zh active Active
- 2008-12-08 JP JP2010537542A patent/JP5745274B2/ja active Active
- 2008-12-08 EP EP16161751.9A patent/EP3103813A1/en not_active Withdrawn
- 2008-12-08 CA CA2707026A patent/CA2707026C/en active Active
- 2008-12-08 PL PL08878088.7T patent/PL2217268T3/pl unknown
- 2008-12-08 RU RU2010123049/10A patent/RU2504552C2/ru active
- 2008-12-08 AU AU2008364115A patent/AU2008364115B2/en active Active
- 2008-12-08 DK DK08878088.7T patent/DK2217268T3/en active
- 2008-12-08 EP EP11185989.8A patent/EP2426146B1/en active Active
-
2009
- 2009-06-11 US US12/483,098 patent/US8124089B2/en active Active
-
2010
- 2010-05-26 IL IL205976A patent/IL205976A/en active IP Right Grant
- 2010-06-07 ZA ZA2010/04046A patent/ZA201004046B/en unknown
- 2010-12-17 US US12/971,495 patent/US8241629B2/en active Active
-
2012
- 2012-01-11 US US13/348,366 patent/US8226948B1/en active Active
- 2012-05-17 US US13/474,001 patent/US8361470B2/en active Active
-
2014
- 2014-02-27 JP JP2014036592A patent/JP5848384B2/ja active Active
-
2015
- 2015-07-15 IL IL239947A patent/IL239947A/en active IP Right Grant
- 2015-11-26 JP JP2015230496A patent/JP6027668B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| ES2523194T3 (es) | Anticuerpo monoclonal humano específico para cada tumor | |
| ES2547463T3 (es) | Moléculas de unión a ILT3 y usos de las mismas | |
| CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
| NZ621938A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
| NZ595464A (en) | Alpha-4-beta-7 heterodimer specific antagonist antibody | |
| ES2564252T3 (es) | Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos | |
| NZ604090A (en) | Human anti-b7rp1 neutralizing antibodies | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
| NZ712765A (en) | Antibodies that bind csf1r | |
| PE20110797A1 (es) | Anticuerpos anti mn | |
| NZ599683A (en) | Anti-ilt7 antibody | |
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav | |
| PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| PE20150222A1 (es) | Anticuerpos multiespecificos | |
| NZ607711A (en) | Antibodies directed to her-3 and uses thereof | |
| ATE537190T1 (de) | Hochaffine antikörper gegen den humanen il-6- rezeptor | |
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ547157A (en) | Interferon Alpha Antibodies and their uses |